Abstract.
Purpose: This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. Methods: Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle. Results: Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all values statistically significant, P≤0.001). Irofulven also produced a statistically significant (P≤0.001) increase in the median survival of mice bearing D-456 intracranial xenografts with a 162% increase in median survival. Conclusions: Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evaluation in patients with this neoplasm is warranted.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Friedman, H.S., Keir, S.T., Houghton, P.J. et al. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48, 413–416 (2001). https://doi.org/10.1007/s002800100358
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s002800100358